World Health Organization

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT

Tel. direct: +41 22 791 3878
E-mail: imd_amd@who.int

In reply please refer to: PM/rg

Your reference:

Mr Naveed Ahmed Khan
Amson Vaccines & Pharma (PVT) Ltd.
115, Industrial Triangle, Kahuta road
Islamabad
Pakistan

27 May 2026

Dear Mr Khan,

Notice of revalidation for single use injection devices

Thank you for having submitted the complete dossiers for revalidation during the 2026 annual review (AR) of your products:

PQS No	Product description	Your product reference
E008/048	AD syringe 0.5ml	Apple K1 AD syringe
E008/060	AD syringe 0.5ml	Destroject 0.5ml AD (1000) syringe
E008/075	0.5ml Auto Disable syringe	Apple K-1 3ring AD syringe
E013/084	RUP syringe 2ml	Apple K1 RUP 2ml
E013/085	RUP syringe 5ml	Apple K1 RUP 5ml

We are pleased to inform you that these products are revalidated until 31 May 2027 and will be published accordingly on the Prequalification (PQ) WHO website page:

http://apps.who.int/immunization_standards/vaccine_quality/pqs_catalogue/

We will formally notify you of the date of next year's review in due course.

If any of your time-bound certificates expire before May 2027, you are requested to provide us with the new documents at their time of issue, or in the case that renewal is pending in the following three months, to communicate to PQS the expected renewal date. Please note, the product will not be revalidated until PQS receives the renewed certificate. Any products covered by an ISO that has not been renewed in the previous year will be automatically suspended.

Kindly note that although PQ does not explicitly request active monitoring of product performance, we do require notification of all adverse events and device failures of which you are aware in accordance with our agreement under the terms and conditions of the PQ initiative.

Kindly note:

- The focus of the PQ initiative is progressing from a qualification process based on certificate and license reviews, towards the improvement of products through manufacturing change transparency, CAPAs with more detailed failure reports and risk mitigation.
- A pre-review of submissions will take place four weeks before the Annual Review (on or shortly after the submission deadline). Should the manufacturer be required to provide further information or to complete documentation, they will be advised two to three weeks prior to the AR.
- Reminders:
    - *Confidentiality*: all information provided by the manufacturer will be treated in the strictest confidence.
    - *Completeness*: manufacturers are reminded that incomplete submissions cannot be revalidated and will require further action on their part. A checklist of required submission documents will be included in the Manufacturer Declaration.
    - *Licence/certificate renewal*: manufacturers are requested to ensure business licences and manufacturing certificates are valid, are accompanied by a notarised translation and, when renewal is required, to ensure that valid documents are provided to the PQS Secretariat in line with the AR submission deadline.
    - *Certification validation*: manufacturers are reminded that they are obliged to provide a specific web link to a certificate authentication page for each mandatory certificate. (A general web link is not sufficient.)
    - *Manufacturer declaration*: manufacturers are reminded of the requirement to sign and date the Manufacturer Declaration form in order to validate their submission. Products cannot be recommended for revalidation in the absence of this signature.
    - *Taxonomy*: E003 manufacturers are reminded that PQS requires that the product performance Taxonomy (released 2020) be used to report all performance failures of PQS prequalified products – including as a part of the Annual Review requirement.

Thank you for your continued collaboration.

Yours sincerely,



Mr Paul Mallins
Technical Officer
Assessment of Medical Devices Team
Prequalification Unit